,address1,city,country,phone,fax,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,auditRisk,boardRisk,compensationRisk,shareHolderRightsRisk,overallRisk,governanceEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,heldPercentInsiders,heldPercentInstitutions,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,trailingEps,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,recommendationKey,quickRatio,currentRatio,debtToEquity,returnOnAssets,returnOnEquity,grossProfits,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,Rapsgatan 7E,Uppsala,Sweden,46 1 87 80 88 00,46 1 87 80 88 88,https://www.orexo.com,Drug Manufacturers—Specialty & Generic,Healthcare,"Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is also developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis. In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.",120,"{'maxAge': 1, 'name': 'Mr. Nikolaj  Sorensen', 'age': 50, 'title': 'Pres & CEO', 'yearBorn': 1972, 'exercisedValue': 0, 'unexercisedValue': 0}",9,1,10,1,5,1693526400,86400,4,1.55,1.55,1.55,1.55,1.55,1.55,1.55,1.55,0.0,0.665165,180,180,16,111,111,53919692,1.04,2.58,1.0706,1.39415,0.0,0.0,USD,53344448,-0.30719,21639950,34415800,0.18208,0.38207,1672444800,1703980800,1688083200,-0.79,PNK,EQUITY,ORXOF,ORXOF,OREXO AB,Orexo AB (publ),1365687000,America/New_York,EDT,-14400000,1.55,none,1.65,1.871,417.69,-0.07012,-0.89992994,521700000,0.067,0.84238,-0.12543,0.0,SEK,
1,Rapsgatan 7E,Uppsala,Sweden,46 1 87 80 88 00,46 1 87 80 88 88,https://www.orexo.com,Drug Manufacturers—Specialty & Generic,Healthcare,"Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is also developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis. In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.",120,"{'maxAge': 1, 'name': 'Mr. Fredrik  Jarrsten', 'age': 55, 'title': 'Exec. VP & CFO', 'yearBorn': 1967, 'exercisedValue': 0, 'unexercisedValue': 0}",9,1,10,1,5,1693526400,86400,4,1.55,1.55,1.55,1.55,1.55,1.55,1.55,1.55,0.0,0.665165,180,180,16,111,111,53919692,1.04,2.58,1.0706,1.39415,0.0,0.0,USD,53344448,-0.30719,21639950,34415800,0.18208,0.38207,1672444800,1703980800,1688083200,-0.79,PNK,EQUITY,ORXOF,ORXOF,OREXO AB,Orexo AB (publ),1365687000,America/New_York,EDT,-14400000,1.55,none,1.65,1.871,417.69,-0.07012,-0.89992994,521700000,0.067,0.84238,-0.12543,0.0,SEK,
2,Rapsgatan 7E,Uppsala,Sweden,46 1 87 80 88 00,46 1 87 80 88 88,https://www.orexo.com,Drug Manufacturers—Specialty & Generic,Healthcare,"Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is also developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis. In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.",120,"{'maxAge': 1, 'name': 'Ms. Cecilia  Coupland', 'age': 46, 'title': 'Sr. VP & Head of Operations', 'yearBorn': 1976, 'exercisedValue': 0, 'unexercisedValue': 0}",9,1,10,1,5,1693526400,86400,4,1.55,1.55,1.55,1.55,1.55,1.55,1.55,1.55,0.0,0.665165,180,180,16,111,111,53919692,1.04,2.58,1.0706,1.39415,0.0,0.0,USD,53344448,-0.30719,21639950,34415800,0.18208,0.38207,1672444800,1703980800,1688083200,-0.79,PNK,EQUITY,ORXOF,ORXOF,OREXO AB,Orexo AB (publ),1365687000,America/New_York,EDT,-14400000,1.55,none,1.65,1.871,417.69,-0.07012,-0.89992994,521700000,0.067,0.84238,-0.12543,0.0,SEK,
3,Rapsgatan 7E,Uppsala,Sweden,46 1 87 80 88 00,46 1 87 80 88 88,https://www.orexo.com,Drug Manufacturers—Specialty & Generic,Healthcare,"Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is also developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis. In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.",120,"{'maxAge': 1, 'name': 'Lena  Wange', 'title': 'Investor Relations & Communications Director', 'exercisedValue': 0, 'unexercisedValue': 0}",9,1,10,1,5,1693526400,86400,4,1.55,1.55,1.55,1.55,1.55,1.55,1.55,1.55,0.0,0.665165,180,180,16,111,111,53919692,1.04,2.58,1.0706,1.39415,0.0,0.0,USD,53344448,-0.30719,21639950,34415800,0.18208,0.38207,1672444800,1703980800,1688083200,-0.79,PNK,EQUITY,ORXOF,ORXOF,OREXO AB,Orexo AB (publ),1365687000,America/New_York,EDT,-14400000,1.55,none,1.65,1.871,417.69,-0.07012,-0.89992994,521700000,0.067,0.84238,-0.12543,0.0,SEK,
4,Rapsgatan 7E,Uppsala,Sweden,46 1 87 80 88 00,46 1 87 80 88 88,https://www.orexo.com,Drug Manufacturers—Specialty & Generic,Healthcare,"Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is also developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis. In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.",120,"{'maxAge': 1, 'name': 'Mr. Robert  Ronn', 'age': 46, 'title': 'Sr. VP and Head of R&D', 'yearBorn': 1976, 'exercisedValue': 0, 'unexercisedValue': 0}",9,1,10,1,5,1693526400,86400,4,1.55,1.55,1.55,1.55,1.55,1.55,1.55,1.55,0.0,0.665165,180,180,16,111,111,53919692,1.04,2.58,1.0706,1.39415,0.0,0.0,USD,53344448,-0.30719,21639950,34415800,0.18208,0.38207,1672444800,1703980800,1688083200,-0.79,PNK,EQUITY,ORXOF,ORXOF,OREXO AB,Orexo AB (publ),1365687000,America/New_York,EDT,-14400000,1.55,none,1.65,1.871,417.69,-0.07012,-0.89992994,521700000,0.067,0.84238,-0.12543,0.0,SEK,
5,Rapsgatan 7E,Uppsala,Sweden,46 1 87 80 88 00,46 1 87 80 88 88,https://www.orexo.com,Drug Manufacturers—Specialty & Generic,Healthcare,"Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is also developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis. In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.",120,"{'maxAge': 1, 'name': 'Dr. Edward  Kim M.B.A., M.D.', 'title': 'Chief Medical Officer', 'exercisedValue': 0, 'unexercisedValue': 0}",9,1,10,1,5,1693526400,86400,4,1.55,1.55,1.55,1.55,1.55,1.55,1.55,1.55,0.0,0.665165,180,180,16,111,111,53919692,1.04,2.58,1.0706,1.39415,0.0,0.0,USD,53344448,-0.30719,21639950,34415800,0.18208,0.38207,1672444800,1703980800,1688083200,-0.79,PNK,EQUITY,ORXOF,ORXOF,OREXO AB,Orexo AB (publ),1365687000,America/New_York,EDT,-14400000,1.55,none,1.65,1.871,417.69,-0.07012,-0.89992994,521700000,0.067,0.84238,-0.12543,0.0,SEK,
6,Rapsgatan 7E,Uppsala,Sweden,46 1 87 80 88 00,46 1 87 80 88 88,https://www.orexo.com,Drug Manufacturers—Specialty & Generic,Healthcare,"Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is also developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis. In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.",120,"{'maxAge': 1, 'name': 'Mr. Robert A. Deluca', 'age': 61, 'title': 'Pres of Orexo US Inc', 'yearBorn': 1961, 'exercisedValue': 0, 'unexercisedValue': 0}",9,1,10,1,5,1693526400,86400,4,1.55,1.55,1.55,1.55,1.55,1.55,1.55,1.55,0.0,0.665165,180,180,16,111,111,53919692,1.04,2.58,1.0706,1.39415,0.0,0.0,USD,53344448,-0.30719,21639950,34415800,0.18208,0.38207,1672444800,1703980800,1688083200,-0.79,PNK,EQUITY,ORXOF,ORXOF,OREXO AB,Orexo AB (publ),1365687000,America/New_York,EDT,-14400000,1.55,none,1.65,1.871,417.69,-0.07012,-0.89992994,521700000,0.067,0.84238,-0.12543,0.0,SEK,
7,Rapsgatan 7E,Uppsala,Sweden,46 1 87 80 88 00,46 1 87 80 88 88,https://www.orexo.com,Drug Manufacturers—Specialty & Generic,Healthcare,"Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is also developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis. In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.",120,"{'maxAge': 1, 'name': 'Mr. Jesper  Lind', 'age': 62, 'title': 'Advisor', 'yearBorn': 1960, 'exercisedValue': 0, 'unexercisedValue': 0}",9,1,10,1,5,1693526400,86400,4,1.55,1.55,1.55,1.55,1.55,1.55,1.55,1.55,0.0,0.665165,180,180,16,111,111,53919692,1.04,2.58,1.0706,1.39415,0.0,0.0,USD,53344448,-0.30719,21639950,34415800,0.18208,0.38207,1672444800,1703980800,1688083200,-0.79,PNK,EQUITY,ORXOF,ORXOF,OREXO AB,Orexo AB (publ),1365687000,America/New_York,EDT,-14400000,1.55,none,1.65,1.871,417.69,-0.07012,-0.89992994,521700000,0.067,0.84238,-0.12543,0.0,SEK,
